New England Independent Review Board Joins the WIRB-Copernicus Group
New addition expands WCG's New England presence and increases its expertise in all phases of clinical research
WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced today that New England Independent Review Board (IRB) has joined the group of companies. Based near Boston, MA, New England IRB expands WCG’s presence in the important New England clinical research hub and further increases its expertise in all phases of drug, medical device and behavioral research.
WCG Chairman and CEO Donald A. Deieso, Ph.D., commented, “We are delighted to welcome New England IRB to the WCG family. New England IRB is recognized for its focus on quality – it has an exceptional regulatory and compliance record – and for providing extraordinary, personalized servicetoits customers.” He added, “The level of innovation and clinical research leadership in the New England region has grown substantially in the pharmaceutical and biotech industry. It is important that we provide a strong regional presence for our clients.”
Founded in 1988, New England IRB was one of the first national, central IRBs dedicated to ensuring the rights and welfare of research study participants.
“We are excited to begin this new phase in New England IRB’s growth,” said New England IRB President James Saunders. “We can now offer our clients access to technologies and processes that will make the clinical trial process more efficient.”
New England IRB will continue to operate independently and will retain its leadership, personnel, and brand. WCG will provide New England IRB with access to technologies, capital and corporate support.
New England IRB joins Western IRB (WIRB), Copernicus Group IRB, Midlands IRB, Aspire IRB, and IRBNet as a member of the WCG family of companies. With the addition of New England IRB, WCG has 14 individual IRB panels, all accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), reviewing clinical research.
“Having maintained its AAHRPP accreditation since 2004, New England IRB has demonstrated itself as a very high quality review board,”said AAHRPP President and CEO Elyse Summers, J.D. “WCG’s commitment to human subjects’ protection and AAHRPP accreditation across its wide spectrum of clients redounds ultimately to the benefit of the volunteers who make the entire human research enterprise possible,” she added.
Financial details about the transaction were not disclosed.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
